Immunic (IMUX) Stock Price
Immunic Price
Analysts set a median price target of 4.08 USD, implying 74.1% below the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. Over the past year Immunic shares have gained 95.9%. The stock trades about 209% above its 52-week low.
Immunic stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Immunic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immunic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immunic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Immunic Price |
|---|---|
| 8/30/2026 | 15.77 USD |
| 8/28/2026 | 15.28 USD |
| 8/27/2026 | 16.37 USD |
| 8/26/2026 | 16.49 USD |
| 8/25/2026 | 16.42 USD |
| 8/24/2026 | 16.62 USD |
| 8/21/2026 | 16.50 USD |
| 8/20/2026 | 16.10 USD |
| 8/19/2026 | 16.77 USD |
| 8/18/2026 | 16.56 USD |
| 8/17/2026 | 16.03 USD |
| 8/14/2026 | 16.06 USD |
| 8/13/2026 | 16.58 USD |
| 8/12/2026 | 15.21 USD |
| 8/10/2026 | 14.10 USD |
| 8/7/2026 | 14.30 USD |
| 8/6/2026 | 14.54 USD |
| 8/5/2026 | 13.99 USD |
| 8/4/2026 | 14.21 USD |
| 8/3/2026 | 14.10 USD |
| 7/31/2026 | 13.97 USD |
| 7/30/2026 | 13.99 USD |
| 7/29/2026 | 12.95 USD |
| 7/27/2026 | 13.77 USD |
| 7/23/2026 | 14.28 USD |
| 7/22/2026 | 15.11 USD |
| 7/21/2026 | 15.15 USD |
| 7/20/2026 | 15.00 USD |
| 7/17/2026 | 15.16 USD |
| 7/16/2026 | 15.03 USD |
Immunic Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunic Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEk USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | 0.01 | 0.01 | 0.08 | 0.22 | 0.40 | 1.58 |
| – | – | – | – | – | – | – | – | – | – | – | – | 558.33 | 172.15 | 86.51 | 294.01 |
| – | – | – | – | – | – | – | – | – | – | -8.33 | -8.33 | -1.27 | -0.47 | -0.25 | -0.06 |
| -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 | -1,000.00 |
| -41.00 | -52.00 | -42.00 | -37.00 | -48.00 | -91.00 | -119.00 | -99.00 | -98.00 | -103.00 | -114.00 | -119.00 | -14.00 | 96.00 | 421.00 | – |
| – | – | – | – | – | – | – | – | – | – | -950.00 | -991.67 | -17.72 | 44.65 | 104.99 | – |
| -40.00 | -52.00 | -41.00 | -34.00 | -44.00 | -92.00 | -120.00 | -93.00 | -100.00 | -97.00 | -432.00 | -288.00 | -294.00 | -70.00 | 180.00 | 179.00 |
| -23.08 | 30.00 | -21.15 | -17.07 | 29.41 | 109.09 | 30.43 | -22.50 | 7.53 | -3.00 | 345.36 | -33.33 | 2.08 | -76.19 | -357.14 | -0.56 |
| 0.08 | 0.11 | 0.11 | 1.07 | 2.12 | 2.53 | 3.18 | 4.46 | 9.02 | 15.57 | 15.57 | 15.57 | 15.57 | 15.57 | 15.57 | 15.57 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Immunic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immunic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immunic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Immunic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immunic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Immunic stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunic Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunic business model & stock analysis
Immunic SWOT Analysis
Strengths
Immunic Inc possesses several strengths that contribute to its success and competitive advantage in the market. These strengths include:
- Strong pipeline of innovative pharmaceutical products.
- Robust research and development capabilities.
- Experienced and talented team of professionals.
- Strategic partnerships with industry leaders.
- Strong financial position and access to funding.
Weaknesses
Despite its strengths, Immunic Inc also faces some weaknesses that may hinder its growth and performance. These weaknesses include:
- Relatively small market presence compared to major competitors.
- Limited marketing and distribution capabilities.
- Dependence on a few key products for revenue generation.
- Potential regulatory challenges and uncertainties.
- Vulnerability to changes in healthcare policies and regulations.
Opportunities
Immunic Inc can capitalize on various opportunities to further enhance its market position and generate growth. These opportunities include:
- Increasing demand for innovative treatments in the pharmaceutical industry.
- Expanding market potential across different therapeutic areas.
- Global expansion and entering new geographic markets.
- Collaboration opportunities with academic institutions and research organizations.
- Advancements in technology and digital health solutions.
Threats
Immunic Inc must also consider various threats that could impact its business and market position negatively. These threats include:
- Intense competition from existing and emerging pharmaceutical companies.
- Rapidly changing market dynamics and evolving customer preferences.
- Potential intellectual property infringements and legal disputes.
- Uncertainty surrounding healthcare reforms and pricing pressures.
- Possibility of adverse side effects or safety concerns of its products.
Immunic Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunic Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Immunic historical P/E ratio, EBIT multiple, and P/S ratio
Immunic annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Immunic shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunic stock splits
Current Immunic forecasts and price targets in September 2026
Analyst Price Targets 2026Immunic Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/22/2026 | Maintained | Buy | – | |
| 4/30/2026 | Maintained | Buy | – | |
| 4/15/2026 | Downgrade | BuyHold | – | |
| 3/2/2026 | Maintained | Buy | – | |
| 2/13/2026 | Maintained | Buy | – | |
| 2/9/2026 | Maintained | Buy | – | |
| 1/7/2026 | Maintained | Buy | – | |
| 11/14/2025 | Maintained | Buy | – | |
| 11/13/2025 | Maintained | Buy | – | |
| 9/26/2025 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Immunic Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2026 | -1.22USD | - | 0.00USD | - | 2026 Q2 |
| 5/13/2026 | -0.93USD | - | 0.00USD | - | 2026 Q1 |
| 2/19/2026 | -0.09USD | - | 0.00USD | - | 2025 Q4 |
| 5/9/2024 | -0.49USD | - | 0.00USD | - | 2024 Q1 |
| 2/21/2024 | -0.51USD | - | 0.00USD | - | 2023 Q4 |
| 8/2/2023 | -0.54USD | - | 0.00USD | - | 2023 Q2 |
| 5/8/2023 | -0.53USD | - | 0.00USD | - | 2023 Q1 |
| 2/22/2023 | -0.76USD | - | 0.00USD | - | 2022 Q4 |
| 11/3/2022 | -0.67USD | - | 0.00USD | - | 2022 Q3 |
| 8/4/2022 | -0.73USD | - | 0.00USD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Immunic stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Immunic shareholder structure
| % | Name |
|---|---|
0.68539% | |
0.63626% | |
0.61552% | |
0.55698% | |
0.53626% | |
0.50742% |
Immunic Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
21.38% | SEC ↗ | |
21.38% | SEC ↗ | |
13.56% | SEC ↗ | |
13.56% | SEC ↗ | |
13.56% | SEC ↗ | |
13.56% | SEC ↗ | |
13.56% | SEC ↗ | |
13.56% | SEC ↗ | |
13.56% | SEC ↗ | |
9.99% | SEC ↗ |
Immunic Executives and Management Board
16 members · avg. age 57 · 31 % women
Dr. Daniel Vitt (56)
Chief Executive Officer, Director · since 2019
2.94 M USD
Management
Dr. Andreas Muehler (61)
Chief Medical Officer
Mr. Glenn Whaley (57)
Chief Financial Officer
Mr. Jason Tardio (48)
President, Chief Operating Officer
Dr. Hella Kohlhof (52)
Chief Scientific Officer
Mr. Inderpal Singh (59)
General Counsel
Mr. Werner Gladdines (46)
Chief Development Officer
Board of Directors
Dr. Duane Nash (54)
Executive Chairman of the Board · since 2012
Mr. Barclay Phillips (62)
Lead Independent Director
Ms. Simona Skerjanec (60)
Independent Director
Dr. Joerg Neermann (58)
Independent Director
Ms. Tamar Howson (76)
Independent Director
Ms. Maria Toernsen (46)
Independent Director
Frequently asked questions about Immunic
Immunic Inc is primarily present in the United States.
Immunic Inc represents a strong commitment to advancing the treatment of autoimmune diseases and chronic inflammatory conditions. The company's corporate philosophy is centered around pioneering innovative therapies that address unmet medical needs, backed by extensive research and development. Immunic Inc prioritizes patient-centricity, aiming to enhance quality of life through effective and safe treatment options. With a focus on excellence and scientific rigor, Immunic Inc strives to deliver groundbreaking therapies that can make a meaningful difference in patients' lives.
The business model of Immunic Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company aims to leverage its deep understanding of the immune system and expertise in small molecule drug development to create potential treatments that target specific diseases. Through its research and development efforts, Immunic Inc. seeks to address unmet medical needs and improve the lives of patients suffering from a range of disorders, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. By combining scientific knowledge with a patient-centered approach, the company strives to provide effective and accessible therapies in the field of immunology.
Immunic Inc is primarily active in the pharmaceutical industry.
The main competitors of Immunic Inc in the market are [insert competitor names here].
Immunic Inc. is a pharmaceutical company specializing in the development of innovative therapies for autoimmune diseases and chronic inflammatory disorders. Founded in 2016, Immunic Inc. has quickly emerged as a key player in the field. The company is focused on leveraging its expertise in small molecule drug development to address unmet medical needs. Immunic Inc. is committed to advancing its pipeline of potential treatments, utilizing a targeted approach to modulate the immune system and provide patients with novel therapeutic options. With a strong dedication to research and development, Immunic Inc. aims to make a significant impact on patients' lives and contribute to the advancement of healthcare.
Immunic Inc, a leading biopharmaceutical company, has reached several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its novel therapeutic candidate, IMU-838, in patients with relapsing-remitting multiple sclerosis. The encouraging results demonstrated its potential in reducing disease activity and progression. Additionally, Immunic Inc achieved the initiation of Phase 2 clinical trials for IMU-935, an orally available small molecule targeting chronic inflammatory and autoimmune diseases. These milestones represent the company's commitment to developing innovative therapies addressing unmet medical needs. Immunic Inc continues to advance its pipeline, striving to provide effective treatments for patients globally.
Analysts currently set an average price target of 5.48 USD for the Immunic stock (median: 4.08 USD), implying -61.5 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Immunic stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immunic to generate revenue of 12.50 M USD and earnings per share of -27.76 USD.
Converted at the current exchange rate, the Immunic share trades at 13.62 EUR (15.77 USD).
The Immunic share (IMUX) is listed on 5 stock exchanges, including: NASDAQ (IMUX), Frankfurt (10VA.F), München (10VA.MU), Düsseldorf (10VA.DU).
Immunic Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of immune and inflammatory diseases.The company's business model is based on four main pillars: research and development, clinical studies, product distribution, and partnerships.
The expected revenue of Immunic is 12.50 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Immunic is -432.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Immunic is currently -0.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immunic stock.
The price-to-sales ratio (P/S) of Immunic is currently 19.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immunic stock.
The Eulerpool Quality Score for Immunic is 2/10.
The ISIN of Immunic is US4525EP1011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immunic is A2PHD4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immunic is IMUX. The ticker symbol is used to trade Immunic shares on the stock exchange.
Immunic paid dividends every year for the past 0 years.
Immunic is assigned to the 'Health' sector.
The dividends of Immunic are distributed in USD.
Immunic stock
Immunic Peer Group
Immunic Ticker
Immunic FIGI
All fundamentals and in-depth analysis of Immunic
Our stock analysis for Immunic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.